{"id":"W2594646846","doi":"10.1016/s2352-3026(17)30019-4","title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Health Services","funders":"Gilead Sciences; Lymphoma Research Foundation","keywords":"Ofatumumab; Idelalisib; Medicine; Internal medicine; Population; IGHV@; Clinical endpoint; Chronic lymphocytic leukemia; Ibrutinib; Rituximab; Clinical trial; Oncology; Gastroenterology; Lymphoma; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002577946,0.002494402,0.004611185,0.0005781699,0.0006681593,0.001970759,0.001223698,0.00262363,0.005617452],"category_scores_gemma":[0.001927524,0.001004303,0.003419393,0.0005901035,0.002107101,0.00225697,0.0005909182,0.005190067,0.001631327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00158999,"about_ca_system_score_gemma":0.001170734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001253291,"about_ca_topic_score_gemma":0.002432638,"domain_scores_codex":[0.9989452,0.0005341771,0.0000576335,0.0001837148,0.00007811447,0.0002011729],"domain_scores_gemma":[0.9987934,0.0003331969,0.0002523516,0.0001126734,0.00006107748,0.0004473242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9810281,0.003141744,0.0005874559,0.0003644333,0.00115085,0.00004904908,0.00004981612,0.0002959302,0.001806335,0.00007515772,0.0005856184,0.01086535],"study_design_scores_gemma":[0.946014,0.05106906,0.001315894,0.00002499535,0.0004462846,0.00004751973,0.00001944554,0.0002486877,0.0001843417,0.0001178666,0.0004949644,0.00001692556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872425,0.006819674,0.000490904,0.0007230265,0.0006446709,0.00146378,0.0008016573,0.0001046441,0.00170924],"genre_scores_gemma":[0.9888263,0.002718147,0.0009707826,0.001135321,0.0004801356,0.002078755,0.001403422,0.00003472808,0.002352508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005617452,"threshold_uncertainty_score":0.01879221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09379685803426602,"score_gpt":0.4174588566744332,"score_spread":0.3236619986401672,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}